Biopharma Manufacturing ‘Turbulence’ Boosts Inquiries for India-Based Providers, Local CDMO Execs Say

India-based CDMOs have detected an uptick in biopharma client interest in their biologics and early-phase clinical offerings – and these manufacturers are accordingly adjusting their growth strategy. “There’s an increase in demand. There’s a lot of factors that are going on that are influencing that,” Enzene Biosciences’ CEO Himanshu Gadgil told Endpoints News in an interview. Enzene especially has seen an increase in small to midsize biopharma clients reaching out. “We will definitely be looking at being more aggressive in terms of our expansion plan,” he added.

Read the full article: Biopharma Manufacturing ‘Turbulence’ Boosts Inquiries for India-Based Providers, Local CDMO Execs Say //

Source: https://endpts.com/biopharma-manufacturing-turbulence-boosts-inquiries-for-india-based-providers-local-cdmo-execs-say/

Leave a Comment

Your email address will not be published.

Scroll to Top